Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anna Offersgaard

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Emerging Microbes & Infections|October 15, 2025
SARS-CoV-2 Mpro inhibitor ensitrelvir: asymmetrical cross-resistance with nirmatrelvir and emerging resistance hotspotsYuyong Zhou, Karen A Gammeltoft, Helena D Tjørnelund-Sjursen, et al.
Hepatology (Baltimore, Md.)|September 3, 2022
Identification of novel neutralizing determinants for protection against HCVGarazi P Alzua, Anne F Pihl, Anna Offersgaard, et al.
Gut|August 2, 2022
Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in miceGarazi Pena Alzua, Anne Finne Pihl, Anna Offersgaard, et al.
Vaccines|July 2, 2021
SARS-CoV-2 Production in a Scalable High Cell Density BioreactorAnna Offersgaard, Carlos Rene Duarte Hernandez, Anne Finne Pihl, et al.
Science Advances|December 21, 2022
Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture systemYuyong Zhou, Karen Anbro Gammeltoft, Line Abildgaard Ryberg, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 7, 2025
Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoproteinLaura Radić, Anna Offersgaard, Tereza Kadavá, et al.
Scientific Reports|July 24, 2024
An inactivated SARS-CoV-2 vaccine based on a Vero cell culture-adapted high-titer virus confers cross-protection in small animalsAnna Offersgaard, Carlos R Duarte Hernandez, Yuyong Zhou, et al.
Ebiomedicine|February 21, 2025
Intranasal recombinant protein subunit vaccine targeting TLR3 induces respiratory tract IgA and CD8 T cell responses and protects against respiratory virus infectionKatharina Wørzner, Signe Tandrup Schmidt, Julie Zimmermann, et al.
Iscience|January 16, 2023
An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animalsAnna Offersgaard, Carlos Rene Duarte Hernandez, Shan Feng, et al.
Nature|July 5, 2023
Hepatitis C virus RNA is 5'-capped with flavin adenine dinucleotideAnna V Sherwood, Lizandro R Rivera-Rangel, Line A Ryberg, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Emerging Microbes & Infections|October 15, 2025
SARS-CoV-2 Mpro inhibitor ensitrelvir: asymmetrical cross-resistance with nirmatrelvir and emerging resistance hotspotsYuyong Zhou, Karen A Gammeltoft, Helena D Tjørnelund-Sjursen, et al.
Hepatology (Baltimore, Md.)|September 3, 2022
Identification of novel neutralizing determinants for protection against HCVGarazi P Alzua, Anne F Pihl, Anna Offersgaard, et al.
Gut|August 2, 2022
Inactivated genotype 1a, 2a and 3a HCV vaccine candidates induced broadly neutralising antibodies in miceGarazi Pena Alzua, Anne Finne Pihl, Anna Offersgaard, et al.
Vaccines|July 2, 2021
SARS-CoV-2 Production in a Scalable High Cell Density BioreactorAnna Offersgaard, Carlos Rene Duarte Hernandez, Anne Finne Pihl, et al.
Science Advances|December 21, 2022
Nirmatrelvir-resistant SARS-CoV-2 variants with high fitness in an infectious cell culture systemYuyong Zhou, Karen Anbro Gammeltoft, Line Abildgaard Ryberg, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 7, 2025
Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoproteinLaura Radić, Anna Offersgaard, Tereza Kadavá, et al.
Scientific Reports|July 24, 2024
An inactivated SARS-CoV-2 vaccine based on a Vero cell culture-adapted high-titer virus confers cross-protection in small animalsAnna Offersgaard, Carlos R Duarte Hernandez, Yuyong Zhou, et al.
Ebiomedicine|February 21, 2025
Intranasal recombinant protein subunit vaccine targeting TLR3 induces respiratory tract IgA and CD8 T cell responses and protects against respiratory virus infectionKatharina Wørzner, Signe Tandrup Schmidt, Julie Zimmermann, et al.
Iscience|January 16, 2023
An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animalsAnna Offersgaard, Carlos Rene Duarte Hernandez, Shan Feng, et al.
Nature|July 5, 2023
Hepatitis C virus RNA is 5'-capped with flavin adenine dinucleotideAnna V Sherwood, Lizandro R Rivera-Rangel, Line A Ryberg, et al.
Pageof 2